These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2860235)

  • 21. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
    Kishino S; Nomura A; Itoh S; Nakagawa T; Takekuma Y; Sugawara M; Furukawa H; Todo S; Miyazaki K
    Eur J Clin Pharmacol; 2002 Dec; 58(9):621-8. PubMed ID: 12483455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Pike E; Lunde PK
    Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Displacement of lidocaine from human plasma proteins by disopyramide.
    Bonde J; Jensen NM; Burgaard P; Angelo HR; Graudal N; Kampmann JP; Pedersen LE
    Pharmacol Toxicol; 1987 Feb; 60(2):151-5. PubMed ID: 3575249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding interaction between enantiomers of disopyramide and mono-N-dealkyldisopyramide on plasma protein.
    Takahashi H; Ogata H; Seki Y
    Drug Metab Dispos; 1991; 19(2):554-7. PubMed ID: 1676669
    [No Abstract]   [Full Text] [Related]  

  • 25. Displacement of disopyramide from human plasma proteins.
    Pedersen LE; Bonde J
    Acta Pharmacol Toxicol (Copenh); 1985 Sep; 57(3):223-6. PubMed ID: 4061102
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of electrocardiographic response and disposition of R- and S-disopyramide in the rabbit.
    Huang JD; Oie S
    Res Commun Chem Pathol Pharmacol; 1983 Aug; 41(2):227-41. PubMed ID: 6635318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of silica gel with aqueous eluent for simultaneous high performance liquid chromatographic assay of disopyramide and mono-N-dealkyldisopyramide.
    Wang LH; Kushida K; Ishizaki T
    Ther Drug Monit; 1986; 8(1):85-9. PubMed ID: 3008386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma free fatty acids and protein binding of disopyramide during haemodialysis.
    Horiuchi T; Johno I; Kitazawa S; Goto M; Hata T
    Eur J Clin Pharmacol; 1987; 33(3):327-9. PubMed ID: 3691623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
    Caplin JL; Johnston A; Hamer J; Camm AJ
    Eur J Clin Pharmacol; 1985; 28(3):253-5. PubMed ID: 4007029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.
    Echizen H; Saima S; Ishizaki T
    Br J Clin Pharmacol; 1987 Aug; 24(2):199-206. PubMed ID: 3620294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-step isolation method for six glycoforms of human alpha1-acid glycoprotein by hydroxylapatite chromatography and study of their binding capacities for disopyramide.
    Kishino S; Nomura A; Saitoh M; Sugawara M; Iseki K; Kitabatake A; Miyazaki K
    J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):1-6. PubMed ID: 9448056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disopyramide concentrations in saliva.
    Aitio ML; Virtanen R; Lammintausta R
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients.
    Chu JS; Kishion S; Nomura A; Miyazaki K
    Zhongguo Yao Li Xue Bao; 1997 Sep; 18(5):408-10. PubMed ID: 10322928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein.
    Hanada K; Ohta T; Hirai M; Arai M; Ogata H
    J Pharm Sci; 2000 Jun; 89(6):751-7. PubMed ID: 10824133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total and free disopyramide by fluorescence polarization immunoassay and relationship between free fraction and alpha-1 acid glycoprotein.
    Chen BH; Taylor EH; Pappas AA
    Clin Chim Acta; 1987 Feb; 163(1):75-80. PubMed ID: 3552331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Accumulation of a disopyramide metabolite in renal failure].
    Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of disopyramide enantiomers for sites on plasma protein.
    Lima JJ
    Life Sci; 1987 Dec; 41(26):2807-13. PubMed ID: 3695808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum alpha-1-acid glycoprotein and protein binding of disopyramide in patients with congestive heart failure.
    Nomura A; Yasuda H; Kobayashi T; Kishino S; Kohri N; Iseki K; Miyazaki K
    Eur J Clin Pharmacol; 1992; 42(1):115-6. PubMed ID: 1541309
    [No Abstract]   [Full Text] [Related]  

  • 40. Lipophilicity Influences Drug Binding to α1-Acid Glycoprotein F1/S Variants But Not to the A Variant.
    Hanada K
    Drugs R D; 2017 Sep; 17(3):475-480. PubMed ID: 28646384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.